New Excellent Technology(NET)
Item Authorization
InnoMyCirco vaccine
Components
- Mycoplasma hyopneumoniae HID3140
- Recombinant P97 protein derived from Mycoplasma hyopneumoniae
- Mycoplasma hyorhinis HID3224
- Recombinant PCV2d Protein
- IMS1313
Efficacy and effectiveness
- Prevention of Swine Mycoplasma Pneumonia
- Prevention of PMWS by Porcine Circovirus type 2 (PCV2)
- Enhanced safety with no side effects
Usage and Capacity
- 1 injection of 2mL into a pig of 3 weeks or older
- Shake enough vaccine before use
InnoMyCirco
- Highly effective vaccine preventing Swine Mycoplasma Pneumonia and Porcine Circovirus type 2 (PCV2) infection (New Excellent Technology:NET certification)
- World’s first Swine Mycoplasma Vaccine with 3 antigens (Mhp, P97, and Mhr) registered by U.S. Patents
- World’s first Vaccine with virus-like particle antigen based on new PCV2d genotype
- Single-vaccine simultaneously protecting against Mhp, Mhr and PCV2, eliminating the need for mixing
Product Overview
| Product Name | InnoMyCirco |
|---|---|
| Time for vaccination | 1 inoculation to pigs over 3 weeks old |
| Vaccination method | Injection once by Intramuscular injection with 2mL of vaccine |
| Efficacy and effectiveness | Prevention of Swine Mycoplasma Pneumonia and prevention of infection by Porcine Circovirus type 2 (PCV2) |
Product Properties
A combined vaccine containing the optimal adjuvant, IMS1313 (Seppic) that has proven safe and effective
| Protection against Swine Mycoplasma | Protection against Porcine Circovirus type 2 |
|---|---|
|
|
Product Distinct Value
- Quantitative Comparison Test conducted with global vaccines validates the superiority of neutralized antibodies and average daily weight gains
- InnoMyCirco vaccine distinguishes itself from the existing commercial vaccines
- Demonstrates superior induction of antibodies in serum against Swine mycoplasma
- Shows exceptional levels of neutralizing antibodies in serum against PCV2, resulting in improved daily weight gains